Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Academic Article uri icon

Overview

MeSH Major

  • Leukemia, Hairy Cell
  • Skin Neoplasms

abstract

  • Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone. (Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505 .).

publication date

  • October 5, 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1709684

PubMed ID

  • 28889792

Additional Document Info

start page

  • 1345

end page

  • 1356

volume

  • 377

number

  • 14